The government has given the green light to the complex trial of a Chinese vaccine as efforts are under way to bring in a potential candidate from India once it is mass produced. He also asked about the vaccine that Russia approved last month.
As a member of a partnership led through the World Health Organization, Bangladesh is about to get a vaccine once its distribution is approved.
But the protection and efficacy of candidate vaccines are still in doubt, and the effects of trials will take months or even years to come out.
“Bangladesh is doing everything that is mandatory to get vaccinated and we are no others,” said Professor ABM Khurshid Alam, Director General of Health Services.
More than two hundred studies are being conducted worldwide in the hope of finding a COVID-19 vaccine, part of which is in the last phase of human trials.
The six career leaders are the aspiring ones developed through the University of Oxford and the British company AstraZeneca; Modern American corporate; a collaboration between the US pharmaceutical company Pfizer and the German company BioNTech; and CanSino Biological, SinoVac Biotech and SinoPharm from China.
The Russian Gamaleya Institute has become the first to obtain the mild green to produce its vaccine, its latest trials are still ongoing.
Mushtuq Husain, who completed his doctoral studies at the University of Cambridge and recently advised Bangladeshi government disease firm IEDCR on combating COVID-19, said the country will have to maintain all the functions open to receiving the vaccine.
He believes the main precedent has been to inspire the progression of a vaccine in the country.
But now focus on participating in the clinical trial procedure with as many prospective vaccines as possible, he told bdnews24. com.
“This is because many vaccines will not be effective. No one can say now what will be effective. If we participate in the rehearsals, we will temporarily notice their effectiveness,” he said.
PLAN COVAX
The COVAX plan, co-led through GAVI, WHO and the CEPI Coalition for Innovations in Epidemic Preparedness, aims to deliver two billion doses of effective and approved COVID-19 vaccines until the end of 2021.
The vaccine allocation plan will acquire and distribute vaccines fairly. It now has an interim agreement with Japan, Germany, Norway and 70 other countries to purchase COVID-19 vaccines through the facility for their populations.
Recently, COVAX has nine COVID-19 candidate vaccines in its portfolio, a variety of other technologies and clinical approaches.
Many countries will pay for vaccines from their public budgets and their spouse with 90 poorer countries, Bangladesh, supported through voluntary donations to GAVI’s COVAX Advanced Market Commitment (AMC).
WHO, first, aims to vaccinate 20 per cent of the population in these countries once a vaccine is approved.
Health Services Branch officials said countries with a consistent source of income of more than $4,000 will have to buy a vaccine, while those with a consistent source of income of less than $4,000 will get express amounts of loose doses in advance.
Below the 20 cent quota, Bangladesh may initially get 34 million doses. Doctors and other frontline staff will be vaccinated first.
GAVI will report at the end of this month whether Bangladesh will get all loose doses or make a partial payment.
Currently, the government will pay 10 percent of the value of vaccines for diseases, while GAVI will run the rest of the costs.
It will take at least until June or July next year for Bangladesh to get the vaccine, depending on the good luck of the trials, GAVI, told bdnews24. com The Minister of Health, Zahid Maleque.
As a component of efforts to get the vaccine before this period, the government is communicating with other countries prioritizing one, he said.
“We will collect the vaccine as soon as possible and anywhere we can,” he added.
CHINESE VACCINE
The government approved phase III trials of a vaccine developed through Sinovac in China at the end of August.
The plan is to first check the vaccine on doctors, nurses, and other fitness workers.
The International Center for Diarrheal Disease Research, Bangladesh, or icddr, b will conduct the trial with approximately 4,200 volunteers over 18 months.
Government approval came more than a month after the Bangladesh Medical Research Council gave the go-ahead.
The government has raised security considerations for the delay.
Sinovac completed a mid-term (phase II) exam in which he said the candidate vaccine gave the impression of being and induced detectable immune responses based on antibodies in subjects.
After being contacted through Sinovac about human testing of his vaccine, icddr, b stated that the Dhaka School of Medicine Hospital, Mugda General Hospital, Mahanagar General Hospital, Kurmitola General Hospital, Kuwait-Bangladesh Friendship Hospital and Sacred Family Hospital had been tested.
INDIAN SERUM INSTITUTE
AstraZeneca has extended its agreement with Oxford Biomedica to mass produce its COVID-19 vaccine, the mobile treatment company announced Tuesday.
The trials are in stages in Britain, Brazil, South Africa, the United States and India, and are also planned more in Japan and Russia.
The Indian Serum Institute, which has signed agreements to mass produce the possible vaccine, said it would set the value of the vaccine at $3 according to the dose for the country and other emerging economies.
India’s Foreign Secretary Harsh Vardhan Shringla, a recent stopover in Dhaka, said the country will prioritize Bangladesh in the distribution of the Oxford vaccine once it is approved.
Subsequently, Beximco Pharmaceuticals of Bangladesh began discussions with the Serum Institute with the only distributor of the vaccine in Bangladesh.
“The merit of the Serum Institute is that it works with 3 candidate vaccines, in addition to that of Oxford,” said Salman F Rahman, Beximco’s vice president and prime minister’s advisor for private sector industry and investment.
A de Beximco did not give main points on how many vaccines the company can receive.
“Now we will have to negotiate with them [Serum] in quantity, value for the personal sector and value to the government,” Salman said.
“There will be a component of other people who will even need to buy the vaccine. And it might not make sense for the government to provide the loose vaccine to those who can. The government has limited resources,” he said, additionally.